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characteristics but treated with external 
beam radiotherapy (RT). All were diagnosed 
between 1994 and 1998. HRQL data were 
collected 5–10 years after diagnosis. Patients 
completed generic- (Short Form-36) and 
cancer-specific (Quality of Life – Cancer 
Survivors) HRQL instruments, and symptom 





Patients on AS were comparable to those 
treated with RT for most generic- and 
disease-specific HRQL dimensions. Patients 














 0.001), more bother with bowel function, 
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 0.005). Multivariate regression 
analyses (corrected for comorbidity and 
clinical disease progression) indicated that 
the management strategy independently 
predicted differences in physical functioning, 
bodily pain, spiritual and total well-being, and 
bowel function and bowel bother.
CONCLUSIONS
 
Patients managed expectantly at initial 
diagnosis (AS) have comparable HRQL and a 
lower symptom burden than patients treated 




active surveillance, disease progression, 
external beam radiotherapy, health-related 
quality of life, prostate cancer
Study Type – Therapy (outcomes research) 




To assess and identify factors associated 
with the long-term health-related quality of 
life (HRQL) of prostate cancer survivors 
managed expectantly, as patients with low-
risk prostate cancer can be managed with 
active surveillance (AS), but research on 




From the population-based Eindhoven 
Cancer Registry, 71 men managed with 
AS were matched with 71 survivors who 
had similar demographic and clinical 
INTRODUCTION
 
PSA testing has increased the early detection 
of low-risk localized prostate cancer, defined 













10 ng/mL [1,2]. However, 
most of these low-risk prostate cancers are 
clinically insignificant and pose a minimal 
threat to health or life [1].
Low-risk prostate cancer can be treated with 
curative treatment or managed expectantly 
with active surveillance (AS) [3]. However, 
low-risk prostate cancers are often indolent; 
as such, patients could be over-treated with a 
curative procedure at diagnosis [2,4], and its 
associated complications could impair health-
related quality of life (HRQL) [3,5]. AS is a 
less invasive alternative and refers to the 
systematic monitoring of men with low-risk 
prostate cancer for whom curative treatment 
is deferred at diagnosis, and who receive 
subsequent curative treatment when the 
tumour shows progression [6] or when 
patients decide to change the treatment [7]. 
AS is distinct from watchful waiting, which 
refers to the palliative treatment of men with 
prostate cancer for whom the tumour is 
too advanced for curative treatment at 
diagnosis [6].
Although associated with fewer treatment-
induced side-effects, recommending AS for 
managing low-risk prostate cancer is 
controversial. Studies suggest that living with 
untreated cancer, and undergoing repeated 
PSA testing and prostate biopsy, increase the 
patients’ feelings of anxiety and uncertainty 
compared with patients who received curative 
treatment at diagnosis [8–10]. In a study 
with a 3-year follow-up, patients under 
surveillance with greater anxiety were 
more likely to select treatment within the 
observation period independent of changes in 





found that patients under AS had no greater 
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psychological distress than those who 
received hormone therapy or radiotherapy 
(RT) [12].
However, studies of AS on long-term HRQL, 
symptoms and psychological morbidity 
compared with curative treatment are 
relatively scarce. The limitations of these 
studies include the qualitative nature, short 
follow-up from diagnosis, or poor sample 
definition with the inclusion of both low- and 
high-risk patients [5,8,10,12].
The objectives of the present study were to 
compare the HRQL and symptoms of a 
population-based sample of long-term 
prostate cancer survivors who opted for 
expectant management at diagnosis, with 
patients who had RT, and predict the effect of 
the management strategy at diagnosis on 





All eligible patients diagnosed with prostate 
cancer between 1994 and 1998 were 
identified from the Eindhoven Cancer Registry 
(ECR). The ECR records data on all patients 
newly diagnosed with cancer in the south of 
the Netherlands, an area with 2.3 million 
inhabitants, 10 hospitals with 18 locations 
and two large RT institutes [13]. After 
excluding all persons who had died before 1 
November 2004 (according to the Central 
Bureau for Genealogy, which collects 
information on all deceased Dutch citizens via 
the civil municipal registries), data collection 
started in November 2004. Approval for this 
study was obtained from a local certified 
Medical Ethics Committee. Additional details 
of the study methods were described 
elsewhere [14,15].
Between 1994 and 1998, AS was not yet 
a standard recommended management 
strategy for low-risk prostate cancer in the 
region covered by the ECR. As was done 
previously [16,17], we selected a sample of 
patients diagnosed with low-risk prostate 
cancer who would be suitable for 
management with AS according to 
contemporary practice. For the purpose of the 
present study, we termed this group ‘AS’ and 









2 as determined 
with a biopsy at diagnosis. These patients 
thereafter received either no active treatment 
or at most, a TURP after diagnosis. AS patients 
were matched with patients who had received 
external beam RT as a primary treatment at 
diagnosis on (a) cancer stage, (b) tumour 




 2 years), and (d) 




 2 years). 
Similarly, RT patients were initially diagnosed 
with a biopsy and subsequently had active 
treatment after diagnosis. To achieve 
adequate power for the study we limited our 
comparison to RT patients as they were 
similar to AS patients on the matching criteria 
of age and clinical characteristics.
Prostate cancer survivors were informed of 
the study via a letter from their urologist. The 
letter explained that by completing and 
returning the enclosed questionnaire, patients 
had consented to participate in the study and 
agreed to the linkage of the questionnaire 
data with their disease history in the ECR. 
Patients were reassured that not participating 
had no consequences on their follow-up care 
or treatment. A reminder letter was sent 
within 2 months to those not responding.
The Dutch version of the Short-Form-36 (SF-
36) questionnaire was used to assess generic 
HRQL [18]. The eight subscales: physical 
functioning, role limitations due to physical 
health problems, bodily pain, general health 
perceptions, vitality, social functioning, role 
limitations due to mental health problems, 
and general mental health were further 
combined into the physical (PCS) and mental 
(MCS) component summary scores. All scales 
were linearly converted to a 0–100 scale 
according to standard scoring procedures, 
with higher scores indicating better HRQL. For 




5 points (the 
general health domain) [19], 6.5 points (the 
physical domain) and 7.9 points (the mental 
health domain) [20] were considered clinically 
significant or minimal important differences 
(MID). MID for other subscales were 









 indicates a threshold of 
discriminant change in HRQL scores of a 
chronic illness [21]. The internal consistency 
and reliability of all scales were above the 0.70 
criteria recommended for group comparisons.
HRQL issues specific to cancer survivors were 
assessed with the Dutch validated Quality 
of Life – Cancer Survivors (QOL-CS) 
questionnaire [22]. The QOL-CS includes 45 
visual analogue scales, each ranging from 0 
(worst outcome) to 10 (best outcome); these 
45 scales are grouped into four multi-item 
subscales on well-being, i.e. physical, 
psychological, social and spiritual. Norman’s 
rule of thumb was used to determine MID 
[21].
Four urinary and bowel modules of the 
Expanded Prostate Cancer Index (EPIC) were 
used to assess urinary and bowel functioning, 
and urinary and bowel bother [23]. All scores 
were linearly transformed, with a range of 
0–100, with 100 indicating the best level of 
functioning or experiencing no bother. MID 
was determined with Norman’s rule of thumb 
[21].
Sexual functioning was assessed with a Dutch 
‘sexual activities module’ (SAc) to allow 
comparison with the Dutch general 
population. The SAc consists of 12 single 
items which do not add up to a scale [24]. 
Aspects assessed include interest in sexual 
activity, getting and maintaining an erection, 
and the use of erectile dysfunction 
treatments. There are three to five possible 
answer categories for each item.
Besides patients’ sociodemographics, clinical 
information available from the ECR was 
included. The ECR routinely collects data on 
tumour characteristics, including date of 
diagnosis, tumour grade according to the 
TNM clinical classification [25], clinical stage 
[25], treatment, and patient background 
characteristics, including date of birth and 
comorbidity at the time of diagnosis (adapted 
from the Charlson comorbidity index) [26].
Information on disease progress (DP) was 
determined in a two-step approach. First, 
patients were asked to report on any DP, 
including the month/year. Affirmative 
answers were then confirmed by staff from 
the cancer registry against ECR records, 
together with information on the date of this 
diagnosis and subsequent radical treatment 
received. Therefore, we only included clinical 
DP which required active treatment in our 
current analysis.
Differences between demographic, clinical 
characteristics, HRQL scores, and symptoms 
function/bother scores between the groups 





-test, as appropriate. Nonparametric 
equivalents were applied when normality and 
homogeneity assumptions were violated. The 
SF-36 and EPIC mean scores of both groups 
were also compared to a Dutch normative 
population. Individual SAc items which 
showed significant differences in frequency 
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between AS and RT were compared to a male 
Dutch normative population [27]. The 
associations between treatment with HRQL 
and symptoms were investigated with linear 
regression models. Comorbidity and DP 
were controlled for in multivariate models. 
















In all, 2348 patients identified from the ECR 
were eligible for the study. Details of the data 
collection process and baseline characteristics 
for the whole sample were reported elsewhere 
[14]. From the whole sample, 1543 were 
diagnosed with prostate cancer, stage 1 or 2. 
Of these patients, 128 (45%) on AS and 265 
(40%) treated with RT were still alive at 1 
November 2004 (data not shown).
Of the 128 AS survivors, 71 returned a 
completed questionnaire and were matched 
with 71 RT patients of similar age and 
comparable disease characteristics; Table 1 
outlines the baseline characteristics of both 
groups. There were no differences on the 
relevant demographic and disease 
characteristics, indicating a successful match. 
Seventeen (24%) AS patients and 13 (18%) RT 
patients had DP. Of the 30 patients with DP, 
nine (six AS; three RT) had missing data on the 
time to DP. Among AS patients, the median 
(interquartile range, IQR) time to DP was 
6.6 (1.5–8.3) years and for RT patients, 
5.7 (4.0–6.4) years. Among 18 patients with 
DP from whom data on subsequent active 
treatment was available, one on AS had a 
radical prostatectomy (RP) and five RT, two 
had hormone therapy, one had both RT and 
hormone therapy. Among RT patients, five had 
RP, one had RT, two had hormone therapy, 
and one both RT and hormone therapy.
The generic HRQL of the AS and RT groups 
were compared with those of a normative 
population, standardized for age and sex 
(Fig. 1); there were no significant differences 
in HRQL scores between the AS group and the 
normative population, but the RT patients had 
significantly lower physical role functioning 
scores than the normative population. Both 
the AS and RT groups had similar generic 
HRQL.
There was no difference in HRQL between AS 
and RT as measured on the QOL-CS (data 
not shown). Further analyses examining 
the two individual items from the QOL-CS 
psychological well-being subscale assessing 
fear (‘Do you feel fearful?’) and depression 
(‘How gloomy or depressed are you?’) showed 
no differences between AS and RT patients 
(results not shown).
Compared with the AS group, the RT group 
had more symptom complaints. The RT 
patients reported significantly poorer bowel 









 0.001) and were more 
bothered by their bowel function, at 








 0.001) (Fig. 2). 
There were MID in bowel bother scores. There 
were no significant differences in urinary 
function and bother between the AS and RT 

















Years from diagnosis 7.9 (1.3) 7.7 (1.1) 0.33
Age at survey, years 75.8 (5.8) 75.9 (5.2) 0.98
Age at survey, %
50–59 1 0







1 48 49 0.86
2 23 22
Tumour grade*, %








Medium 23 23 0.21
High 17 10
Employment status, %
Not working/retired 63 65 0.35
Working 5 5
Comorbidity, %
One 17 25 0.32
Two or more 54 46
Most common comorbid conditions, %
Hypertension 26 15 0.04
Arthritis 19 16 0.56
Asthma 12 16 0.40
DP, %
Yes 17 13 0.41
Median (IQR) years to DP 6.6 (1.5–8.3) 5.7 (4.0–6.4)
 
*Grade was based on the TNM clinical classification [16,25], where Grade 1 is comparable to a Gleason 
score of 2–4 and Grade 2 is comparable to a Gleason score of 5–7. †There were no single patients in our 
sample; ‡Low (no or primary school), medium (lower general secondary education or vocational training), 
high (pre-university education, high vocational training, university).
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population, both the RT and AS groups 
reported significantly poorer urinary function, 
and higher urinary and bowel bother. For 
bowel function, RT patients had significantly 
lower scores than the normative population.
On the SAc items, patients treated with RT 
reported significantly more problems related 
to ‘getting and maintaining an erection in the 
last 2 weeks’ than the AS group and the 
normative population (Fig. 3). There were no 
significant differences between the groups on 
other items of the SAc.
To ensure that the above results were not 
reflective of DP, subanalyses comparing the 
HRQL and symptom burden of RT and AS 
patients without DP were conducted; the 
results remain unchanged (data not shown).
In multivariate regression analyses, 
management strategy was an independent 
predictor of differences in HRQL and 
symptom complaints experienced by low-risk 
prostate cancer survivors (Table 2). RT 
was negatively associated with physical 
functioning and bodily pain dimensions of the 
SF-36. There was also a negative association 
on the QOL-CS spiritual and total well-
being scores of RT patients. On the EPIC 
assessments, there were significant negative 
associations only with bowel function and 
bowel bother among RT patients. Poorer 
scores on various HRQL domains of the SF-36 
and QOL-CS were independently predicted by 
DP and comorbidity.
In subanalyses within the AS group, patients 
with DP had similar scores on most HRQL 
dimensions as those patients without DP at 
the time of survey (data not shown). The only 
HRQL dimensions in which AS patients with 
DP scored significantly and clinically poorer 
than stable patients were on the SF-36 role 
functioning emotional and MCS summary 
dimensions, and QOL-CS total well-being 
scale. There were no differences in urinary and 




Our study showed that long-term survivors of 
localized low-risk prostate cancer managed 
expectantly (AS) had comparable HRQL to 
prostate cancer survivors of similar age and 
clinical manifestation treated with RT. 
Furthermore, AS patients reported fewer 
problems with getting an erection, had better 
bowel functioning, and were less bothered 
with their bowel function than RT patients. 
In addition, the HRQL of AS patients was 
comparable to that in the age- and sex-
matched normative population up to 10 years 
after diagnosis.
The similarity of HRQL scores of AS and RT 
patients up to 10 years after diagnosis is 
comparable to other studies. A randomized 
trial reported no differences in HRQL except 




Comparison of SF-36 scores according to mode of management to the normal population 
standardized for age and sex. An asterisk above a subgroup indicates a difference in the mean score between 





































Comparison of EPIC urinary functioning/bother and bowel functioning/bother scores according to 
mode of management compared to the normal population standardized for age and sex. An asterisk above a 
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survivors treated with RT compared with 
those who deferred treatment [5]. A Swedish 
randomized trial comparing RP with watchful 
waiting also found no differences in HRQL 
between the groups [28].
Both the AS and RT groups in the present 
study had comparable urinary function 
and bother, while only the RT group had 
significantly poorer bowel function and 
higher levels of bother with their bowel 
function. Likewise, patients in the RT arm in 




 [5] had more 
bowel symptoms than the deferred treatment 
group.
Previous, mainly qualitative, studies suggest 
that being managed with AS could increase 
the patients’ psychological morbidity due to 
the untreated cancer [9,10]. In our sample, 
patients managed with AS had equivalent 
levels of psychological well-being as RT 
patients up to 10 years after diagnosis, and 
responses on the individual items of fear and 
depression of the QOL-CS were within normal 
levels, even after considering DP. Similarly, the 
Swedish study comparing RP with watchful 
waiting found no psychological differences 
between the groups at 4 years after 
randomization [28]. It could be suggested that 





increases psychological morbidity but rather 
patients’ psychological state that determines 
treatment selection. A patient with low-risk 
prostate cancer who chooses curative 
treatment such as RT over AS could have 





 [11] showed that anxiety 
and PSA velocity were independent predictors 
of receiving curative treatment in a group of 
localized prostate cancer survivors under 
surveillance. In another study where patients 
with localized prostate cancer were allowed 
to decide between a lower- or higher-dose RT, 
patients with higher anxiety or depression 
levels were more likely to choose more 
aggressive treatment [29]. However prostate 
cancer survivors who regretted their curative 
treatment have poorer HRQL and more 
symptom complaints than those who were 
not regretful [30]. Interestingly, that study, 
patients who had regrets about their 
treatment had lower median PSA levels and 
Gleason scores than those who were not 
regretful. Treatment objectives could differ 
between patients with prostate cancer and 
their physicians [31], and agreement was poor 
when physicians were asked to predict 




Comparison of sexual complaints (%) among prostate cancer survivors with a Dutch male normal 








































RT (n = 63)AS (n = 60) AS (n = 60) RT (n = 60)
Yes, (nearly) always Yes, occasionally No, (almost) never















 coefficients of multivariate analyses indicating the association of management 
strategy of low-risk prostate cancer on HRQL, and urinary/bowel function/bother
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 0.05. GH, general health; PF, physical function; RP, role function, physical; RE, role 
function, emotional; BP, bodily pain; SF, social function; VT, vitality; MH, mental health; Phy, physical well-
being; Psy, psychological well-being; Soc, social well-being; Spi, spiritual well-being; Tot, total well-being; 
UF, urinary function; UB, urinary bother; BF, bowel function; BB, bowel bother.
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results suggest that patients diagnosed with 
low-risk prostate cancer, besides having 
adequate and relevant information on the 
natural history of low-risk prostate cancer 
and its treatment options, could also benefit 
from psychological support in their decision-
making.
Of interest is DP among the AS and RT 
patients in our study. Despite the assumption 
that undergoing RT decreases or eradicates 
possible DP, while AS patients live with 
untreated cancer and therefore risk DP, both 
groups had similar numbers of patients with 
DP. Among patients with a known time to DP, 
those in the AS group had a longer median 
time to progression than the RT group 
(Table 1). Furthermore, in a retrospective 
study of the survival time of men managed 
expectantly, the 10-year prostate cancer-
specific survival was 100% [16]. We 
acknowledge that the psychological burden 
and treatment options after DP could differ 
for AS and RT patients, but the results 
remained similar when DP patients in both 
groups were excluded from the analyses. As 
such, these results, in addition to the increase 
in symptom burden for patients treated with 
RT, suggest these patients could be over-
treated for their localized prostate cancer 
compared with AS patients with similar 
clinical characteristics.
There are several limitations to the current 
study; the inclusion of long-term AS survivors 
could indicate possible survival bias. However, 
as both the AS and RT groups had a similar 
mortality rate (data not shown), we conclude 
that survival bias is unlikely to be a problem. 
Second, although we included patients with 
low cancer stage and grade in the AS group, 
we cannot exclude the possibility of some 
misclassification, as we do not have data on 
Gleason scores and PSA values of these 
patients. We limited our comparison only to 
patients receiving RT. We acknowledge as 
such that we are not able to generalize our 
results to survivors who received other forms 
of curative treatment. Selection bias could 
explain the lack of difference in psychological 
well-being between the groups, as the anxiety 
levels might have decreased over time, or 
those more anxious patients were less likely to 
stay on the AS protocol. Furthermore, the 
cross-sectional design of our study limits the 
determination of a causal association 
between management strategy and HRQL, as 
baseline HRQL at diagnosis before the start of 
management is not known. Moreover, DP was 
established by patients’ self-report and 
thereafter confirmed via the ECR. Therefore, 
under-representation of patients with DP is 
possible, as patients who had progression did 
not report this on the questionnaire. Despite 
these limitations, our current results are 
intriguing and would benefit from further 
investigation using a prospective longitudinal 
design with a long follow-up to detect 
possible clinical DP. Future studies could 
assess the HRQL of men with newly diagnosed 





 form of management strategy, to 
establish a baseline against which follow-up 
assessments could be compared.
Nevertheless, the strong points of our study 
include the HRQL assessment of a population-
based sample managed expectantly up to 
10 years after diagnosis. Our study can 
therefore be considered unique in providing 
information on the long-term effect of 
expectant management on HRQL and 
symptom burden. Moreover, the inclusion of 
DP for consideration when assessing long-
term HRQL in patients managed expectantly 
has, to our knowledge, not been previously 
reported.
In conclusion, patients diagnosed with 
localized low-risk prostate cancer are often 
faced with difficult decisions about their 
treatment options. In our study, patients 
managed expectantly had comparable HRQL 
and a lower symptom burden than RT patients 
up to 10 years after diagnosis, even after 
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